PT  - JOURNAL ARTICLE
AU  - Wessel, Jennifer
AU  - Majarian, Timothy D
AU  - Highland, Heather M
AU  - Raghavan, Sridharan
AU  - Szeto, Mindy D
AU  - Hasbani, Natalie R
AU  - de Vries, Paul S
AU  - Brody, Jennifer A
AU  - Sarnowski, Chloé
AU  - DiCorpo, Daniel
AU  - Yin, Xianyong
AU  - Hidalgo, Bertha
AU  - Guo, Xiuqing
AU  - Perry, James
AU  - O’Connell, Jeffrey R
AU  - Lent, Samantha
AU  - Montasser, May E
AU  - Cade, Brian E
AU  - Jain, Deepti
AU  - Wang, Heming
AU  - Wu, Peitao
AU  - Bonàs-Guarch, Silvia
AU  - D’Oliveira Albanus, Ricardo
AU  - Leong, Aaron
AU  - Miguel-Escalada, Irene
AU  - Varshney, Arushi
AU  - ,
AU  - Kinney, Gregory L
AU  - Yanek, Lisa R
AU  - Lange, Leslie
AU  - Almeida, Marcio
AU  - Peralta, Juan M
AU  - Aslibekyan, Stella
AU  - Baldridge, Abigail S
AU  - Bertoni, Alain G
AU  - Bielak, Lawrence F
AU  - Bowden, Donald W
AU  - Chen, Chung-Shiuan
AU  - Chen, Yii-Der Ida
AU  - Choi, Seung Hoan
AU  - Choi, Won Jung
AU  - Darbar, Dawood
AU  - Floyd, James S
AU  - Freedman, Barry I
AU  - Goodarzi, Mark O
AU  - Irvin, Ryan
AU  - Kalyani, Rita R
AU  - Kelly, Tanika
AU  - Lee, Seonwook
AU  - Liu, Ching-Ti
AU  - Loesch, Douglas
AU  - Manson, JoAnn E
AU  - Nassir, Rami
AU  - Palmer, Nicholette D
AU  - Pankow, James S
AU  - Rasmussen-Torvik, Laura J
AU  - Reiner, Alexander P
AU  - Selvin, Elizabeth
AU  - Shadyab, Aladdin H
AU  - Smith, Jennifer A
AU  - Weeks, Daniel E
AU  - Weng, Lu-Chen
AU  - Xu, Huichun
AU  - Yao, Jie
AU  - Yoneda, Zachary
AU  - Zhao, Wei
AU  - Ferrer, Jorge
AU  - Mahajan, Anubha
AU  - McCarthy, Mark I
AU  - Parker, Stephen
AU  - Alonso, Alvaro
AU  - Arnett, Donna K
AU  - Blangero, John
AU  - Boerwinkle, Eric
AU  - Cho, Michael H
AU  - Correa, Adolfo
AU  - Cupples, L. Adrienne
AU  - Curran, Joanne E
AU  - Duggirala, Ravindranath
AU  - Ellinor, Patrick T
AU  - He, Jiang
AU  - Heckbert, Susan R
AU  - Kardia, Sharon LR
AU  - Kim, Ryan W
AU  - Kooperberg, Charles
AU  - Liu, Simin
AU  - Lubitz, Steven A
AU  - Mathias, Rasika A
AU  - McGarvey, Stephen
AU  - Mitchell, Braxton D
AU  - Morrison, Alanna C
AU  - Peyser, Patricia A
AU  - Psaty, Bruce M
AU  - Redline, Susan
AU  - Roden, Dan
AU  - Shoemaker, M. Benjamin
AU  - Smith, Nicholas L
AU  - Taylor, Kent D
AU  - Vasan, Ramachandran S
AU  - Viaud-Martinez, Karine A
AU  - Florez, Jose C
AU  - Wilson, James G
AU  - Sladek, Robert
AU  - Dupuis, Josée
AU  - Rich, Stephen S
AU  - Rotter, Jerome I
AU  - Meigs, James B
AU  - Manning, Alisa K
TI  - Rare Non-coding Variation Identified by Large Scale Whole Genome Sequencing Reveals Unexplained Heritability of Type 2 Diabetes
AID  - 10.1101/2020.11.13.20221812
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.13.20221812
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20221812.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20221812.full
AB  - Type 2 diabetes is increasing in all ancestry groups1. Part of its genetic basis may reside among the rare (minor allele frequency <0.1%) variants that make up the vast majority of human genetic variation2. We analyzed high-coverage (mean depth 38.2x) whole genome sequencing from 9,639 individuals with T2D and 34,994 controls in the NHLBI’s Trans-Omics for Precision Medicine (TOPMed) program2 to show that rare, non-coding variants that are poorly captured by genotyping arrays or imputation panels contribute h2=53% (P=4.2×10−5) to the genetic component of risk in the largest (European) ancestry subset. We coupled sequence variation with islet epigenomic signatures3 to annotate and group rare variants with respect to gene expression4, chromatin state5 and three-dimensional chromatin architecture6, and show that pancreatic islet regulatory elements contribute to T2D genetic risk (h2=8%, P=2.4×10−3). We used islet annotation to create a non-coding framework for rare variant aggregation testing. This approach identified five loci containing rare alleles in islet regulatory elements that suggest novel biological mechanisms readily linked to hypotheses about variant-to-function. Large scale whole genome sequence analysis reveals the substantial contribution of rare, non-coding variation to the genetic architecture of T2D and highlights the value of tissue-specific regulatory annotation for variant-to-function discovery.Competing Interest StatementAnubha MahajanAs of January 2020, A.M. is an employee of Genentech, and a holder of Roche stock. Patrick T. EllinorDr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular disease. Dr. Ellinor has consulted for Bayer AG, Novartis and Quest Diagnostics. Jose FlorezDr. Florez has received a consulting honorarium from Goldfinch Bio. and speaker fees from Novo Nordisk James S. FloydDr. Floyd has consulted for Shionogi Inc Barry I. FreedmanDr. Freedman is a consultant for RenalytixAI and AstraZeneca Pharmaceuticals Steven A. LubitzDr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer HealthCare, and Boehringer Ingelheim, and has consulted for Abbott, Quest Diagnostics, Bristol Myers Squibb / Pfizer. Ed SilvermanGrant support from GSK and Bayer Michael H. ChoGrant support from GSK; consulting fees from Genentech Bruce M. PsatyPsaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Stella AslibekyanSA holds equity in 23andMe, Inc. Mark I McCarthyThe views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. M.I.MM.McC. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, M.McC. is an employee of Genentech, and a holder of Roche stock.Funding StatementSee Supplementary Tables (SUPPL.TABLES.Funding.13NOV2020.xlsx) for funding statements from TOPMed, study, individual and resources. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study participants provided informed consent, and each study's Institutional Review Board [or ethics review committee] provided approval. Details are provided in provided Supplementary Table (SUPP.TABLE.ParentStudy.Ethics.Statements.xlsx).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on the Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal website. http://t2d.hugeamp.org/